Congress:
ECR25
Poster Number:
C-11371
Type:
Poster: EPOS Radiologist (educational)
Authorblock:
P. Del Nido Recio, A. Paternain Nuin, M. R. López De La Torre Carretero, M. B. Barrio Piqueras, M. Jiménez Vázquez, C. Mbongo, C. Urtasun Iriarte, D. A. Zambrano, J. D. Aquerreta; Pamplona/ES
Disclosures:
Pablo Del Nido Recio:
Nothing to disclose
Alberto Paternain Nuin:
Nothing to disclose
Manuel Rafael López De La Torre Carretero:
Nothing to disclose
Miguel Barrio Barrio Piqueras:
Nothing to disclose
Marcos Jiménez Vázquez:
Nothing to disclose
Carmen Mbongo:
Nothing to disclose
Cesar Urtasun Iriarte:
Nothing to disclose
Daniel Alfonso Zambrano:
Nothing to disclose
Jesús Dámaso Aquerreta:
Nothing to disclose
Keywords:
Haematologic, Musculoskeletal bone, Musculoskeletal soft tissue, MR-Diffusion/Perfusion, PET-CT, Diagnostic procedure, Haematologic diseases
- [1] Filho AGO, Carneiro BC, Pastore D, Silva IP, Yamashita SR, Consolo FD, et al. Whole-body imaging of multiple myeloma: Diagnostic criteria. Radiographics 2019;39:1077–97. https://doi.org/10.1148/rg.2019180096
- [2] Hillengass J, Fechtner K, Weber MA, Bäuerle T, Ayyaz S, Heiss C, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606–10. https://doi.org/10.1200/JCO.2009.25.5356.
- [3] Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma response assessment and diagnosis system (MY-RADS). Radiology 2019;291:5–13. https://doi.org/10.1148/radiol.2019181949
- [4] Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E. 18F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review. Frontiers in Nuclear Medicine 2021;1:808627. https://doi.org/10.3389/fnume.2021.808627
- [5] Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol 2014;83:2203–23. https://doi.org/10.1016/J.EJRAD.2014.09.012.
- [6] Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 2018;45:712–9. https://doi.org/10.1007/S00259-017-3909-8.
- [7] Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. J Clin Oncol 2021;39:116–25. https://doi.org/10.1200/JCO.20.00386.
- [8] Nanni C. PET-FDG: Impetus. Cancers (Basel) 2020;12. https://doi.org/10.3390/CANCERS12041030.
- [9] Moreau P, San Miguel J, Sonneveld P, Mateos M V., Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017;28:iv52–61. DOI: 10.1093/annonc/mdx096 PMID: 28453614.
- [10] Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology 2014;32:3059–67. https://doi.org/10.1200/JCO.2013.54.8800.
